Video

Journal Club VL

Symptomatic and Health Related Quality of Life Benefits With Olaparib in Men With mCRPC Carrying Mutations in the Homologous Recombination Repair Genes, Journal Club - Christopher Wallis & Zachary Kla... Details Christopher Wallis and Zachary Klaassen focus this discussion on the article published in The Lancet titled "Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound)." The authors of this study aimed to assess pain...
Combination Therapy Associated with Significantly Higher Rates of MFS Compared with ADT Alone Among Men with High-Risk Nonmetastatic Prostate Cancer: STAMPEDE Platform Protocol, Journal Club- Christop... Details Christopher Wallis and Zachary Klaassen discuss the publication in the Lancet analyzing new data from the STAMPEDE trial of two randomized controlled phase 3 trials done in a multiarm, multistage platform protocol to assess the efficacy of adding abiraterone and prednisolone alone or with enzalutamide to androgen-deprivation therapy (ADT) in men with high-risk non-metastatic prostate cancer. Biogr...
Efficacy and Safety of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Defects (GALAHAD) Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen highlight the multicentre, open-label, phase 2 GALAHAD trial. In this trial, the authors evaluated the anti-tumour activity and safety of the PARP inhibitor niraparib in patients with metastatic castration-resistant prostate cancers and DNA repair gene defects (DRDs) who progressed on previous treatment with an androgen signaling inhibitor and a taxane. Biog...
The Benefit of ADT Treatment Intensification with Radiotherapy for Men with Localized Prostate Cancer, Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen discuss MARCAP, a meta-analysis of randomized trials in cancer of the prostate. This individual patient data meta-analysis of relevant randomized trials aimed to quantify the benefit of various androgen deprivation therapy (ADT) intensification strategies in men receiving radiotherapy for the treatment of prostate cancer in aggregate and in clinically releva...
PSMA PET CT Derived Risk-Stratification Tool for High-risk Prostate Cancer - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen discuss an article published in JAMA Network Open titled "Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer." This study aimed to evaluate the prognostic significance of a nomogram that models an individual's risk of nonlocaliz...
Racial and Ethnic Disparity in the Use of Prostate MRI - a UroToday Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen review the publication titled "Racial and Ethnic Disparities in the Use of Prostate Magnetic Resonance Imaging Following an Elevated Prostate-Specific Antigen Test." The study evaluated the association between race and ethnicity and the mean time between prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). Among men with elevated PSA results...
Performance of rhPSMA 7.3 (18F) PET Ligand in Suspected Prostate Cancer Recurrence - UroToday Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen discuss the article published in the Journal of Nuclear Medicine reporting on the first retrospective data on the detection efficacy and potential impact of 18F-rhPSMA-7.3 on clinical management in a homogeneous cohort of patients with biochemical recurrence after radical prostatectomy, and prior to any salvage therapy. 18F-rhPSMA-7.3 is under investigation...
Real-World Differences in Outcomes with First-Line Abiraterone Therapy Between African American and White Men with mCRPC - A UroToday Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen discuss the JAMA Oncology article titled "Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone." The authors of this study aimed to investigate the differences in outcomes with first-line abiraterone therapy between African American and non-Hispanic White men with mCRPC in...
Higher Rates of Metastatic Disease on PSMA PET for Biochemical Recurrence Risk Groups, Journal Club - Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine article titled "PSMA PET Validates Higher Rates of Metastatic Disease for European Association of Urology Biochemical Recurrence Risk Groups: an international multicenter study." The authors' findings support the new EAU classification for biochemically recurrent prostate cancer (BCR), that BCR high-risk groups have...
Health-Related Quality of Life- The ENZAMET Trial - A UroToday Journal Club –- Christopher Wallis & Zachary Klaassen Details Christopher Wallis and Zachary Klaassen discuss the International, Randomized Phase III ANZUP ENZAMET trial published in the Journal of Clinical Oncology . In this trial, health-related quality of life (HRQL) was assessed with the European Organisation for Research and Treatment of Cancer core quality-of-life questionnaire and QLM-PR25 at weeks 0, 4, 12, and then every 12 weeks until progression....

Journal Club VL

Login